This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Alzheimer's Disease & Dementia Conference" (Dementia 2025) June 05-07, 2025 | Hybrid Event has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at dementia@magnusconference.com or call + 1 (702) 988 2320.
Alzheimer's disease (AD), the most common form of dementia, is rapidly becoming a major global health concern among the elderly. Multiple pathogenic components and abnormalities in the behavior of various cell types within the CNS play a role in AD pathogenesis. The most well-studied form of neurodegenerative amyloidopathy is Alzheimer's disease (AD). Molecular pathology, aided by genomes and proteomics, is improving our understanding of neurodegenerative disease development, diagnosis, and treatment. The goal of molecular pathology is to uncover disease mechanisms by identifying molecular and pathway changes. The use of old and novel tools established in biochemistry, cell biology, molecular biology, proteomics, and genetics to the evaluation of pathological processes is at the heart of this still-evolving science. The value of molecular pathology as a supplement to histopathology in nonclinical drug development is well understood in the pharmaceutical industry.
Important Alert:
X
Title : Early clinical development of modified P8 for the treatment of alzheimer’s disease
Nazneen N Dewji, Cenna Biosciences Inc, United States
Title : Who cares for the carers
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Memory should be the primary endpoint in early AD
Matthias W Riepe, Ulm University, Germany
Title : Down’s syndrome (trisomy 21) and alzheimer disease: A common medical and scientific fight
London Jacqueline, Paris Diderot University, France
Title : Quality of life children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Efficacy of transcranial photobiomodulation in mild cognitive impairment and early alzheimer’s Disease: A randomized controlled study
Hyelim Chun, St.Peter’s General Hospital, Korea, Republic of